论文部分内容阅读
目的:观察依帕司他与西地那非联合应用治疗2型糖尿病患者勃起功能障碍的疗效。方法:将60例勃起功能障碍的2型糖尿病患者随机分为两组,治疗组(n=30)给予依帕司他与西地那非联合治疗,对照组(n=30)给予西地那非治疗。根据国际勃起功能指数表(IIEF-5)勃起质量量表问卷(EQS),患者进行自我评分。结果:治疗后2组的IIEF-5和EQS评分值较治疗前均显著增加,差异有统计学意义(P<0.01)。治疗组的IIEF-5和EQS评分显著高于对照组,差异有统计学意义(P<0.05)。结论:依帕司他联合西地那非治疗糖尿病勃起功能障碍的疗效优于单一使用西地那非。
Objective: To observe the curative effect of etanercept combined with sildenafil on erectile dysfunction in type 2 diabetic patients. Methods: Sixty patients with type 2 diabetes mellitus with erectile dysfunction were randomly divided into two groups. The treatment group (n = 30) was given combination therapy of epalrestat and sildenafil, and the control group (n = 30) Non-treatment. Patients were self-rated according to the erectile dysfunction questionnaire (EQS) of the International Index of Erectile Function Index (IIEF-5). Results: The scores of IIEF-5 and EQS in two groups after treatment were significantly higher than those before treatment, the difference was statistically significant (P <0.01). The scores of IIEF-5 and EQS in the treatment group were significantly higher than those in the control group, with statistical significance (P <0.05). CONCLUSIONS: The efficacy of epalrestat plus sildenafil in the treatment of diabetic erectile dysfunction is superior to single use of sildenafil.